- Home
- IBRX vs PSNY Comparison
IBRX vs PSNY Comparison
Compare IBRX & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PSNY
- Stock Information
- Founded
- IBRX 2014
- PSNY 2017
- Country
- IBRX United States
- PSNY Sweden
- Employees
- IBRX N/A
- PSNY N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PSNY Auto Manufacturing
- Sector
- IBRX Health Care
- PSNY Consumer Discretionary
- Exchange
- IBRX Nasdaq
- PSNY Nasdaq
- Market Cap
- IBRX 2.4B
- PSNY 2.8B
- IPO Year
- IBRX N/A
- PSNY N/A
- Fundamental
- Price
- IBRX $4.49
- PSNY $1.16
- Analyst Decision
- IBRX Buy
- PSNY Hold
- Analyst Count
- IBRX 2
- PSNY 7
- Target Price
- IBRX $17.38
- PSNY $1.64
- AVG Volume (30 Days)
- IBRX 10.4M
- PSNY 3.6M
- Earning Date
- IBRX 11-12-2024
- PSNY 11-26-2024
- Dividend Yield
- IBRX N/A
- PSNY N/A
- EPS Growth
- IBRX N/A
- PSNY N/A
- EPS
- IBRX N/A
- PSNY N/A
- Revenue
- IBRX $7,332,000.00
- PSNY $2,046,740,000.00
- Revenue This Year
- IBRX $1,563.18
- PSNY $40.97
- Revenue Next Year
- IBRX $1,262.20
- PSNY $94.45
- P/E Ratio
- IBRX N/A
- PSNY N/A
- Revenue Growth
- IBRX 1218.71
- PSNY N/A
- 52 Week Low
- IBRX $3.10
- PSNY $0.61
- 52 Week High
- IBRX $10.53
- PSNY $2.65
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- PSNY 41.41
- Support Level
- IBRX $4.57
- PSNY $1.16
- Resistance Level
- IBRX $5.08
- PSNY $1.30
- Average True Range (ATR)
- IBRX 0.54
- PSNY 0.09
- MACD
- IBRX -0.12
- PSNY 0.00
- Stochastic Oscillator
- IBRX 3.16
- PSNY 21.43
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.